CXCR4 and neoplasm: In 2013, Feig and colleagues theorized that fibroblast cells in the tumor microenvironment (TME) produced the C-X-C motif chemokine 12 (CXCL12), the ligand of CXCR4, which antagonizes and blocks the immune response from killing PDAC cells [9].